ADDITIONAL INFORMATION AND COMPENSATION DISCLOSURE -- Please Read Completely Before Considering An Investment
COMPANY BACKGROUND
H-QUOTIENT, INC. is a publicly traded company that creates and produces state-of-the art computer software systems that collect and act upon real-time information critical to improving the delivery of healthcare. They have also recently announced the acquisition of a healthcare distribution business expected to immediately accretive to earnings (see PR lin below) Company Website: hquotient.com
What exactly do HQNT's products offer clients?
hquotient.com
Significant New Management
** Larry Burden, a former Senior V.P. and CIO of Freddie Mac, has been appointed as VP of Operations to market their medical products, including LabQuotient, which they announced publicly should add $5M Net to their bottom line. (PR link below)
** Dr. Laipply, Nichols Institute at Qeust Diagnostics, has also joined H-Quotient as Chairman of the H-Quotient, Inc., Scientific Advisory Board. (PR link below)
STARTER D.D. -- please conduct and trust only your own Due Diligence
** Two year high/low: $7.00+ to .16 (major seller of 3M shares is done, according to company representatives and DTC's)
** Very little debt (about $200K per CEO)
** Shares O/S = 25M (12M float; 4M “true float”, per CEO)
YAHOO INFO: please be aware yahoo and other links may be out of date.
finance.yahoo.com
RECENT CHART
bigcharts.marketwatch.com.
RECENT DEVELOPMENTS
** Announced unaudited net earnings from operations in excess of $1M; audited financials supposed to be out next week per CEO (See PR link and more info below).
** Announced $5M projected Net for LabQuotient (see PR below)
** Announced a recent acquisition of a healthcare distribution business that the company expects to have an immediate accretive impact on earnings. (see PR link below)
** Added two very high quality team members recently (who presumably did their own DD on the company)
(1) Dr. Thomas Laipply, Dir. of Molecular Tissue Pathology, Nichols Institute at Quest Diagnostics (see recent PR's below) and his share purchases in the open market.
(2) Laurence Burden, V.P. of Operations, to help market HQNT’s medical software products. Look at his resume (from recent PR below)
- "As corporate VP and Chief Information Officer (CIO) and member of the turnaround team, he helped make possible the $2.3 billion sale of Firestone to Bridgestone" Also, "As Senior VP and CIO of Freddie Mac, he redesigned its computer systems and financial engineering systems, providing the basis for hundreds of millions in revenues and savings."
FILING INFO AND RECENT NEWS
Please verify yourself these and other figures below by looking at the current filings at: siliconinvestor.com and especially the new filing when it comes out.
H-Quotient, Inc., Announces Record Annual Earnings
VIENNA, Va., Apr 19, 2002 /PRNewswire-FirstCall via COMTEX/ -- H-Quotient, Inc., (OTC Bulletin Board: HQNT chart, msgs) announced earnings from operations in excess of 1,000,000 for the year ending December 31, 2001, compared with losses in every prior year. Additional earnings were recorded from investments through our subsidiary Quotient Capital Corporation.
siliconinvestor.com
H-Quotient, Inc., Announces LabQuotient; $5 Million Net Projected
VIENNA, Va., Mar 25, 2002 /PRNewswire-FirstCall via COMTEX/ -- H-Quotient, Inc., (OTC Bulletin Board: HQNT chart, msgs) and Dr. Thomas C. Laipply, MD, FCAP, FIAP, Director of Molecular Tissue Pathology, Nichols Institute at Quest Diagnostics announced LabQuotient, a relational database for improving and monitoring medical test ordering. The product is expected to be ready for market this summer. Pre-production orders have been received. Further details will be announced in a subsequent release.
H-Quotient, Inc., is projected to earn net income of $5 million in the product's first year. All income will be recurring and is expected to grow substantially because the universe for this revolutionary product includes clinical doctors, dentists, veterinarians, emergency rooms, urgent care centers, insurance companies, HMOs, hospital quality assurance personnel, commercial laboratories, and pharmaceutical-drug companies.
****
H-Quotient, Inc., Announces Appointment of Laurence T. Burden As V.P. of Operations ---- Check his resume:
siliconinvestor.com
****
H-Quotient, Inc., Announces Scientific Advisory Board Chairman
siliconinvestor.com
****
H-Quotient, Inc., Announces More Than 1 Million Shares Purchased by Dr. Laipply
siliconinvestor.com
****
H-Quotient, Inc. Announces LabQuotient Prototype; Full-Scale Sales Effort to Commence
siliconinvestor.com
****
H-Quotient, Inc., Announces Development of Blood Utilization Software
siliconinvestor.com
****
OTHER NEWS: Recent Acquisition
siliconinvestor.com
Do your own DD. You may want to call Doug Kohn, the CEO, at 703-821-3434
DISCLAIMER: PLEASE READ BEFORE CONSIDERING AN INVESTMENT IN H-QUOTIENT: As always, do your own Due Diligence. The information posted by me is believed to be accurate, but cannot be guaranteed. Some forward-looking statements or opinions expressed by myself or others on this thread or others may not prove to be true. I was retained by the company on April 9th, 2002, and AM BEING COMPENSATED by the Company with 15K shares of restriced stock. This means I cannot sell any of the shares until at least April of 2003. My goal is to help bring some honest exposure to it and try to attract longer term shareholders who believe in its potential after doing their own Due Diligence. Some may not want to invest in H-Quotient because of that or at least factor my involvement in their decision. I also currently hold 6,500 shares of stock that I purchased on the open market from 57 to 74 cents recently.
New investors should be especially cautious when considering an investment, short or long term, in a low-priced stock on the OTC/Bulletin Board. Please visit the SEC'S website at sec.gov
thanks,
Dave (Bob) |
